Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Genitourinary cancer neoadjuvant therapies: current and future approaches
Sujit S. Nair
, Dimple Chakravarty
, Vaibhav Patel
,
Nina Bhardwaj
,
Ashutosh K. Tewari
Icahn School of Medicine at Mount Sinai
Urology
Cancer Immunology
Genetics and Genomic Sciences
Graduate School of Biomedical Sciences
Icahn Genomics Institute
Marc and Jennifer Lipschultz Precision Immunology Institute
Medicine
Medicine - Hematology and Medical Oncology
Mount Sinai Tisch Cancer Center
Cancer Clinical Investigation
Research output
:
Contribution to journal
›
Review article
›
peer-review
13
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Genitourinary cancer neoadjuvant therapies: current and future approaches'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Neoadjuvant Therapy
100%
Genitourinary Cancer
100%
Imaging Studies
25%
Clinical Trials
25%
Tumor Volume
25%
Treatment Response
25%
Bladder Cancer
25%
Prostate Cancer
25%
Neoadjuvant
25%
Tolerability
25%
Drug Response
25%
Cancer Therapy
25%
Genitourinary Malignancies
25%
Locally Advanced
25%
Subsequent Therapy
25%
Renal Cancer
25%
Design Considerations
25%
Neoadjuvant Setting
25%
Treatment-naïve Patients
25%
Anticancer Treatment
25%
Neoadjuvant Trials
25%
Survival Endpoint
25%
Pharmacology, Toxicology and Pharmaceutical Science
Urogenital Tract Cancer
100%
Malignant Neoplasm
50%
Neoplasm
50%
Biological Marker
50%
Clinical Trial
50%
Recurrent Disease
50%
Tolerability
50%
Prostate Cancer
50%
Bladder Cancer
50%
Kidney Cancer
50%
Medicine and Dentistry
Neoadjuvant Therapy
100%
Urogenital Tract Cancer
100%
Recurrent Disease
25%
Clinical Trial
25%
Neoplasm
25%
Cancer
25%
Bladder Cancer
25%
Cancer Therapy
25%
Biological Marker
25%
Prostate Cancer
25%
Treatment Response
25%
Kidney Cancer
25%
Drug Response
25%
Nursing and Health Professions
Neoadjuvant Therapy
100%
Urogenital Tract Cancer
100%
Imaging
25%
Tumor Volume
25%
Recurrent Disease
25%
Bladder Cancer
25%
Cancer Therapy
25%
Biological Marker
25%
Treatment Response
25%
Prostate Cancer
25%
Kidney Cancer
25%
Anticancer
25%